Baseline (18)F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.: 18F-FDG PET indices for therapy response by Hatt, Mathieu et al.
Baseline (18)F-FDG PET image-derived parameters for
therapy response prediction in oesophageal cancer.
Mathieu Hatt, Dimitris Visvikis, Olivier Pradier, Catherine Cheze-Le Rest
To cite this version:
Mathieu Hatt, Dimitris Visvikis, Olivier Pradier, Catherine Cheze-Le Rest. Baseline (18)F-
FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.:
18F-FDG PET indices for therapy response. European Journal of Nuclear Medicine and Molec-
ular Imaging, Springer Verlag (Germany), 2011, 38 (9), pp.1595-1606. <10.1007/s00259-011-
1834-9>. <inserm-00595534>
HAL Id: inserm-00595534
http://www.hal.inserm.fr/inserm-00595534
Submitted on 25 May 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
 Baseline 18F-FDG PET image derived parameters for 
therapy response prediction in oesophageal cancer 
 
Mathieu Hatt1, Dimitris Visvikis1, Olivier Pradier1,2, Catherine Cheze-le Rest1 
 
1INSERM, U650 LaTIM, 2Department of Radiotherapy, CHU Morvan, Brest, France 
 
Running title: 18F-FDG PET indices for therapy response  
 
Keywords: oesophageal cancer, response to therapy, PET scan, tumour volume, 
total lesion glycolysis 
 
Corresponding author: 
Mathieu HATT 
 LaTIM, INSERM U650 
 CHU MORVAN 
 5 avenue Foch 
 29609 Brest 
 France 
 Tel.:+33298018111 
 
Wordcount: 5206 
 
 2 
ABSTRACT 
 Background: The objectives of this study were to investigate the predictive 
value of tumour measurements on 18F-FDG PET pretreatment scan regarding 
therapy response in oesophageal cancer and to evaluate the impact of tumour 
delineation strategies.  
 Methods: 50 patients with oesophageal cancer treated with concomitant 
radio-chemotherapy between 2004 and 2008 were retrospectively considered and 
classified as complete, partial or non responders (including stable and progressive 
disease) according to RECIST. The classification of partial and complete responders 
was confirmed by biopsy. Tumours were delineated on the 18F-FDG pretreatment 
scan using an adaptive threshold and the automatic Fuzzy Locally Adaptive Bayesian 
(FLAB) methodologies. Several parameters were then extracted: maximum and peak 
SUV, tumour longitudinal length (TL) and volume (TV), mean SUV, and Total Lesion 
Glycolysis (TLG=TV×mean SUV). The correlation between each parameter and 
response was investigated using Kruskal-Wallis tests and receiver operating 
characteristic methodology was used to assess performance of the parameters to 
differentiate patients. 
 Results: Whereas commonly-used parameters such as SUV measurements 
were not significant predictive factors of the response, parameters related to tumour 
functional spatial extent (TL, TV, TLG) allowed significant differentiation of all three 
groups of patients, independently of the delineation strategy, and could identify 
complete and non responders with sensitivity above 75% and specificity above 85%. 
A systematic although not statistically significant trend was observed regarding the 
hierarchy of the delineation methodologies and the considered parameters, with 
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slightly higher predictive value obtained with FLAB over adaptive thresholding, and 
TLG over TV and TL. 
 Conclusions: TLG is a promising predictive factor of concomitant radio-
chemotherapy response with statistically higher predictive value than SUV 
measurements in advanced oesophageal cancer. 
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1. Introduction 
Oesophageal cancer is the third most common malignancy of the digestive 
tract and a leading cause of cancer mortality worldwide with an estimated 5-year 
survival of 15% [1]. Despite the progress made to better understand this disease, its 
incidence is steadily increasing and there is a growing concern regarding its effective 
management [2]. The best chance for cure remains surgical resection. However, 
many patients have already an advanced disease (locally advanced oesophageal 
carcinoma: LAEC) at diagnosis and may benefit in terms of survival from neoadjuvant 
therapy prior to surgery [3]. The maximum benefit is for those patients who achieve a 
complete pathological response with no residual cancer cells in the primary tumour or 
lymph nodes [4]. A complete response occurs only in 15-30% of cases and is 
associated with an increased overall survival [5]. On the other hand, patients who do 
not respond to therapy may be unnecessarily affected by toxicity of an inefficient 
therapy [6]. Therefore, the development of a diagnostic test offering non invasive 
response to therapy prediction early in the course of treatment is of a great interest, 
allowing potential personalization of patient management as for un-operable tumours, 
chemotherapy and/or radiation therapy remains the only option. Such an assessment 
becomes more critical when one considers new targeted drugs that could be tested 
with higher efficiency if applied early [7]. For oesophageal cancer several histological 
markers such as the tumour suppressor factor gene p53, the proliferative marker 
Ki67, and the epidermal growth factor receptor, have been evaluated for the 
prediction of the therapeutic response prior to neoadjuvant therapy. None of these 
markers or a combination of them can currently predict response with sufficient 
accuracy [8-9]. Positron Emission Tomography (PET) imaging with 2-(18F)fluoro-2-
deoxy-D-glucose (18F-FDG) allows the visualization of the enhanced glucose 
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metabolism in viable oesophageal cancer cells and may be of interest within this 
context. 18F-FDG PET is already well established for staging of oesophageal cancer 
with a better sensitivity and specificity than the combined use of CT and endoscopic 
ultrasonography (EUS) to detect distant metastases [10]. PET has also been shown 
to be promising in assessing response to therapy [11]. Several studies have shown 
that the reduction of the tumour’s metabolic activity as measured by the standard 
uptake value (SUV) from the baseline to the end of therapy uptake is predictive of a 
better outcome with however a large variability in the sensitivity and specificity [12]. In 
addition, a correlation between clinical outcome and a metabolic response observed 
as early as within the first 2 weeks of treatment has been demonstrated [13]. These 
findings suggest that tumour activity concentration differences measured on serial 
18F-FDG PET scans could possibly be used to individualize treatment. However, it 
could be more cost-effective and beneficial to the patient to be able to predict therapy 
response from a single baseline PET scan acquired before the initiation of the 
treatment. The current study was therefore carried out to investigate the potential 
value of baseline 18F-FDG PET image derived parameters for the prediction of 
response to combined radio-chemotherapy in oesophageal cancer. A secondary 
objective was to investigate the potential influence of the method used to delineate 
the tumour on the prediction results.  
2. Material and methods 
2.1 Patients 
50 consecutive patients with newly diagnosed oesophageal cancer treated with 
exclusive concomitant radio-chemotherapy between 2004 and 2008 were included in 
this study. As part of the routine procedure for the initial staging in oesophageal 
cancer, each patient was referred for an 18F-FDG PET study before treatment. It 
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included three courses of 5-fluorouracil/cisplatin and a median radiation dose of 60Gy 
given in 180cGy daily fractions delivered once daily, 5 days a week for 6-7 weeks. 
The characteristics of the patients are given in table 1. Most of them (45 out of 50) 
were male, aged 65±9 years at the time of diagnosis. 74% of the tumours, most of 
which were squamous cell carcinoma (72%), originated from the middle and lower 
oesophagus. Response to therapy was evaluated 1 month after the completion of the 
concomitant radio-chemotherapy using conventional thoraco-abdominal CT and 
endoscopy. Patients were classified as non responders (NR) including stable and 
progressive disease, partial responders (PR) or complete responders (CR). 
Response evaluation was based on CT evolution between pre-treatment and post-
treatment scans using RECIST (Response Evaluation Criteria in Solid Tumours) [14]. 
Patients also underwent fibroscopy in case of partial or complete response. Complete 
response was confirmed by the absence of visible disease in the high endoscopy and 
no viable tumor on biopsy. Partial CT response was confirmed by macroscopic 
residual (>10% viable) on biopsy. No discordance was observed between 
pathological, when available, and CT evaluation. 
The current analysis was carried out after an approval by the institutional ethics 
review board. 
 
2.2 18F-FDG PET acquisitions 
All 18F-FDG PET studies were carried out prior to the initiation of treatment. Patients 
were instructed to fast for at least 6h before the 18F-FDG administration (5MBq/kg). 
Static emission images were acquired from head to thigh (2min per bed position) 
beginning 60min after injection on a Philips GEMINI PET/CT system (Philips Medical 
Systems, Cleveland, OH USA). Images were reconstructed using the RAMLA 3D 
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algorithm and CT based attenuation correction. Optimized reconstruction parameters 
were used for the RAMLA 3D based on the standard optimized clinical protocol (2 
iterations, relaxation parameter of 0.05, 5mm 3D Gaussian post-filtering, 4x4x4mm3 
voxels grid sampling). The PET images were corrected for attenuation using CT 
based attenuation correction. 
 
2.3 PET image analysis 
All considered parameters were extracted from the baseline PET images only. For 
each patient, the primary tumour was identified on the baseline pre-treatment PET 
images by a nuclear physician. Three different SUV measurements and three 
parameters related to the tumour functional dimensions, namely the tumor volume 
(TV), tumour longitudinal length (TL) and total lesion glycolysis (TLG) [15] were 
extracted for each primary lesion. SUV measurements considered were SUVmax, 
SUVpeak defined as the mean of SUVmax and its 26 neighbors (roughly similar to a 
1cm ROI), and mean SUV within the delineated tumour (SUVmean). Whereas SUVmax 
and SUVpeak are clearly independent of the tumour delineation strategy used, TL, TV, 
SUVmean and the derived TLG values might depend on the delineation process. To 
study the impact of this step, we considered two different approaches; namely the 
automatic Fuzzy Locally Adaptive Bayesian (FLAB) algorithm [16-17] and an 
adaptive threshold algorithm [18] optimized for the GEMINI PET/CT scanner. 
Although the first approach is fully automatic, adaptive thresholding requires a 
manually defined background region of interest (ROI). Therefore two experienced 
nuclear medicine physicians were considered in the background ROI definition, 
leading to two series of results denoted as TA1 and TA2. TL was determined in 
longitudinal direction by multiplying the number of slices in the delineated tumour 
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volume by the PET image slice thickness (4mm). TV was defined as the sum of all 
voxels contained in the delineated volumes multiplied by the image voxel’s volume 
(64mm3). Finally, TLG was determined by multiplying the SUVmean and associated 
TV.  
 
2.4 Statistical analysis 
The relation between response to therapy and each parameter distribution was 
studied using the Kruskal-Wallis test [19] as recommended for small, not normally 
distributed samples. 
Receiver operating characteristic (ROC) methodology [20] was used to assess 
the performance of each parameter to differentiate patients. Two classification tasks 
were considered: differentiating CR patients from PR and NR, or NR patients from 
CR and PR. Evaluation was performed in terms of the area under the curve (AUC) as 
well as specificity and sensitivity.  
The significance of the following factors was tested: age, gender, T, N, and M 
classifications, AJCC (American Joint Committee on Cancer) stage, histology types, 
SUVmax, SUVpeak, TL, TV, SUVmean, and TLG. All tests were two-sided and p values 
<0.05 were considered statistically significant. 
 
3. Results  
The range of values for the different image derived indices as well as the mean and 
standard deviation for the patient population considered are given in table II. All 
primary lesions were detected by 18F-FDG PET exhibiting a rather high uptake with a 
SUVmax of 9.7±3.9. SUVpeak and SUVmean measurements were comparatively lower 
(8.0±3.3 and 5.8±2.4 respectively). 
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Correlation between image derived indices and between methodologies 
TV and TL measurements were moderately correlated (r=0.77, 0.68 and 0.60 
for FLAB, TA1 and TA2 respectively, p<0.0001). On the other hand, no significant 
correlation was found between TV and any of the SUV measurements (r<0.2, p>0.1), 
irrespective of the delineation approach used. High correlations were observed 
between the TV (r>0.89), TL (r>0.90) or TLG (r>0.93) measurements obtained with 
the two delineation strategies (p<0.0001). Even higher correlation coefficients 
(r>0.97, p<0.0001) were observed for the SUVmean measurements derived using the 
two different tumour segmentation approaches (FLAB and adaptive thresholding). 
Despite these correlations, certain large differences were observed for few patients 
between the delineation results of the two segmentation algorithms considered, 
examples of which are illustrated in figure 1. 
 
Response to therapy analysis 
Out of the 50 patients included in the study 25 were classified as PR, while 
there were 12 CR and 13 NR. Results concerning the predictive value of all 
considered parameters are summarized in tables III and IV containing the results of 
the Kruskal-Wallis tests and that of the ROC analysis (considering the AUC, 
specificity and sensitivity regarding the classification tasks) respectively.   
Age, gender, or T, N, M classifications did not allow significant prediction of 
the response to treatment. The AJCC stage was not significantly (p>0.05) associated 
with the type of response, despite the fact that all NR were at least stage IIB and 
could be statistically differentiated from both PR and CR (p<0.05). However, AJCC 
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stage could not differentiate PR from CR (p>0.05). Finally, there was no statistical 
correlation between histology type and response (p=0.3). 
Figure 2 shows a graphical comparison of the Kruskal-Wallis results 
considering the predictive value of the different SUV parameters considered. Initial 
SUVmax (fig 2.A) was not predictive of response to therapy (p=0.29) although CR 
tended to have smaller SUVmax (8.1±4.1) than PR and NR (10.2±3.7 and 10.2±3.9 
respectively). Similarly, SUVpeak (fig 2.B) was not predictive of response to therapy 
with a mean value of 6.5±3.5 in CR, whereas both PR and NR were characterized by 
similar higher SUVpeak values (8.5±3.1 and 8.4±3.3 respectively) (p=0.14). None of 
the SUVmean measurements, whatever delineation strategy was used, could 
significantly predict response to therapy (p>0.19).  
On the contrary, all parameters related to tumour spatial extent (TL, TV and 
TLG) measurements allowed significant (p<0.002) differentiation of the three 
response groups, irrespective of the segmentation methodology (see figure 3.A-C). 
For instance, TV as measured by FLAB was 20±25, 32±24 and 72±40 cm3 for CR, 
PR and NR patients respectively. The parameter that allowed the best differentiation 
between the three patient groups was TLG measured by FLAB (K-W test p<0.0001, 
see figure 3.C), with a TLG of 74±75g, 179±143g and 385±226g for CR, PR and NR 
patients respectively. Figure 4 shows examples of one CR, one PR and one NR 
patient with corresponding TLG values.  
The ROC analysis results confirmed the limited predictive value of most SUV 
measurements for the accurate classification of either CR vs. PR and NR, or NR vs. 
PR and CR (AUC<0.70 and <0.56 respectively). Differences between ROC analysis 
associated with SUV measurements and those associated with TL, TV and TLG was 
significant (p<0.05) for both tasks (see examples in figure 5). Better predictive 
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performances were obtained with TL, TV and TLG measurements with significantly 
higher AUC (from 0.74 to 0.86) for both tasks (p<0.05). For instance, using FLAB a 
TLG <58g allowed identifying complete responders with a sensitivity of 75% and a 
specificity of 92%, and a TLG >196g identified NRs with a sensitivity of 76% and a 
specificity of 85%. However in terms of predictive performance no significant 
differences were obtained between TL, TV and TLG measurements for both tasks. In 
terms of an observed trend, better results were obtained for TLG over TV and TL 
whatever tumour delineation approach was used (tables III and IV). In addition there 
was a systematic although not statistically significant trend of better performance for 
those parameters when obtained with FLAB compared to the use of the adaptive 
threshold, as demonstrated by higher AUC and smaller confidence intervals, as well 
as higher sensitivity and specificity for both classification tasks (table IV). 
The analysis with respect to histology type (adenocarcinoma vs. squamous cell 
carcinoma) led to similar results with what was observed when considering the entire 
population. Within the same context no statistically significant differences were 
observed between the two patient groups in the hierarchy of parameters and results 
derived using the different functional tumour volume delineation methods.  
The predictive value of TLG, combining TV and SUVmean into one single 
parameter, was higher than the one of tumour volume, despite the non-significant 
value of SUVmean alone. Considering together TV and SUVmean, one is able to 
differentiate different treatment response patient groups (see figure 6). On the one 
hand, TLG increased the differentiation between CR and NR, as all NR had either a 
TV above 50cm3 (8/13) or a SUVmean above 5 (8/13), while 10 out of 12 CR had 
either a small TV (<15cm3) (9/12) or SUVmean
 (<5) (7/12), and half of them (6/12) had 
both. On the other hand, PR had either a higher SUVmean
 than CR for volumes below 
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25cm3 (6.5±2.7 vs. 4.5±2.4), or lower SUVmean than NR for TV of 25-50cm
3 (5.8±1.8 
vs. 7.1±0.9). Therefore the use of TLG increased the differentiation between PR and 
CR, as well as between PR and NR for volumes below 15cm3 and between 25 and 
50cm3 respectively. 
4. Discussion  
Assessment of response to therapy early during treatment plays an important role 
in patient management as well as in drug development and new criteria including 
PET have been suggested for this task [21-22]. However, being able to predict 
response to therapy before the initiation of the treatment would be even more 
powerful for patient management. In this context, either patient or tumour 
characteristics could be considered. In our study we focused on functional imaging 
and different image derived parameters related to tumour uptake using PET. The 
results of our study demonstrate that tumour volume based parameters derived from 
baseline FDG PET images in oesophageal cancer are good predictors of response to 
therapy, with high TL, TV and TLG being associated with poor response to combined 
radio-chemotherapy. On the contrary, more commonly used parameters such as 
tumour SUVs were not predictors of response to therapy considering only the 
baseline FDG PET images. These results further demonstrate the value of tumour 
volume based PET image derived parameters, since we have previously 
demonstrated a superior prognostic value of baseline functional TL, TV and TLG over 
SUV measurements for overall survival on a similar group of oesophageal cancer 
patients [23]. 
FDG PET has been previously used for the prediction of response to therapy 
or prognosis in a variety of malignancies [24]. Considering the predictive value of 
baseline FDG uptake for therapy response in oesophageal cancer, only few data 
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showing conflicting results are available [12]. Levine et al. and Rizk et al. reported a 
high initial SUVmax being associated with good response [25-26], whereas Makino et 
al. and Kato et al. found the opposite [27-28]. These conflicting results can be 
potentially attributed to differences in patient populations, tumour histology types, as 
well as treatment, but could also suggest that SUV measurements are unreliable in 
this context. Although similarly to the results of Kato et al. and Makino et al., our 
results suggest that lower values of SUVmax are associated with a complete 
response, this trend was not significant. In addition, SUVmean or SUVpeak, considered 
more robust to potential noise bias associated with SUVmax, were also not significant 
predictors of response to therapy in our study. 
One of the demonstrated independent predictors of long term survival in 
oesophageal cancer is longitudinal tumour extension established by pathological 
examination [29]. It has been previously demonstrated that TL measured on CT 
images leads to a weak correlation with the pathological TL, associated with a large 
overestimation [30]. Some authors proposed the estimation of metabolic TL as a 
surrogate of pathological TL using various thresholds of 18F-FDG PET uptake [31] 
however conflicting results concerning the predictive value of metabolic TL for 
response to neoadjuvant radio-chemotherapy have been observed [32-33]. One may 
argue that TL does not reflect the entire volume of the tumour and could therefore be 
only considered as a limited surrogate measure of tumour functional spatial extent. 
This assumption is partly supported by our data, in which only a moderate correlation 
(r between 0.6 and 0.77) was found between TV and TL, suggesting that TV may 
bring additional information compared to TL in assessing overall tumour burden. In 
our study both TV and TL were found to be significant predictive factors of response 
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to therapy, irrespective of the functional volume delineation strategy, with only a small 
and non significant improvement of the predictive value of TV over TL. 
TV and TLG measured on PET are 3D measurements incorporating metabolically 
active tumour volume not available from CT data [34]. It has already been 
demonstrated that a decrease of the TV and TLG can predict response to therapy 
[35-36]. These studies however have explored differences in indices derived from 
serial PET images. The value of such indices obtained on the baseline scan only 
within the context of therapy response prediction in oesophageal cancer has not 
previously been explored. Because these parameters reflect metabolic information in 
the entire tumour, they may be more accurate for tumour characterization than a 
single voxel measure and this may explain why TV and TLG were good predictors of 
therapy response as demonstrated in our study. Our results are consistent with 
recent studies in pleural mesothelioma and lymphoma patients that have 
demonstrated the potential of such indices extracted from baseline 18F-FDG PET 
scan to predict response to therapy [37-38]. 
Despite a great potential value, such indices have been only of limited use to 
date, which can be explained by the limited accuracy, robustness and reproducibility 
of the available tumour delineation tools [39-40]. In oesophageal cancer only the 
prognostic value of TV has been studied [23, 41], while there is limited data on the 
value of TLG [23]. In our study TLG allowed identifying complete responders and non 
responders with moderate sensitivity (75% and 76% respectively) and high specificity 
(92% and 85% respectively). Prospective studies with a larger patient population 
using a predictive model built upon our results should now be carried out to 
demonstrate the ability of the parameters to discriminate responders from non 
responders on a patient by patient basis. 
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In our study, TNM stage and AJCC classification were not good predictors of 
therapy response. This could be explained by our suboptimal staging procedure. 
Since we considered only patients referred for exclusive radio-chemotherapy, no 
patient underwent surgery, and therefore no pathological data was available. Staging 
was routinely performed using endoscopic ultrasonography and CT which are known 
to have limited staging performances [10]. 
Our present study has limitations. Firstly, we considered a group of only 50 
patients with predominantly squamous cell carcinomas since it is the most common 
histological type of oesophageal cancer in European countries. An analysis based on 
the tumour histology type considering our patient population did not reveal 
statistically significant differences, although due to the small number of patients with 
adenocarcinomas, these results would obviously need to be confirmed. Secondly, our 
study was inherently limited by its retrospective design and as such some selection 
bias might be present. However, the treatment regime was homogeneous throughout 
the recruited patients since all were treated in a single institution. In addition, within 
this patient population no particular selection criteria were applied. Thirdly, the impact 
of partial volume effects in the measured SUVs was not assessed in this study. The 
lack of partial volume correction might have played a role in the reduced predictive 
value of some of the SUV measurements, although it is unlikely because of the large 
tumour volumes considered in this work (40±35cm3). Lastly, we did consider only 
primary tumours since the measurements used are simpler to perform in routine 
clinical practice compared to measurement of overall tumour burden including 
primary and metastatic lesions. However, given the respective size of metastatic 
lesions and primary tumours, adding metastatic lesions to the overall TLG would not 
significantly alter the resulting values and associated conclusions.  
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5. Conclusion 
Our results demonstrated that 18F-FDG baseline image derived parameters 
related to the metabolic tumour spatial extent (TL, TV and TLG) are good predictors 
of response to therapy in oesophageal cancer with sensitivity above 75% and 
specificity above 85%. Commonly used SUV measurements (max, peak, mean) on 
pre-treatment FDG PET image did not allow statistically significant differentiation of 
the different response patient groups. 
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Figures captions 
 
Figure 1: Illustration of differences in tumour delineation depending on the 
methodology for two patients. 
 
Figure 2: Distributions of NR, PR and CR patients and associated Kruskal-Wallis 
tests for SUV based image derived indices: (A) SUVmax and (B) SUVpeak. 
 
Figure 3: Distributions of NR, PR and CR patients and associated Kruskal-Wallis 
tests for tumour volume related image derived indices: (A) TL (TA2), (B) TV (TA1), and 
(C) TLG (FLAB). 
 
Figure 4: 18F-FDG PET axial, coronal and sagital images of a (A) complete 
responder with 20g TLG, (B) partial responder with 100g TLG and (C) non-responder 
with 750g TLG. 
 
Figure 5: Examples of ROC curves obtained for classification tasks of differentiating 
(A) CR from NR&PR or (B) NR from PR&CR. Comparison of ROC curves for SUV 
measurements (SUVmax in red, SUVpeak in orange and SUVmean in yellow) and TL, TV 
and TLG measured with FLAB (in light blue, blue and dark blue respectively). 
 
Figure 6: Distribution of CR, PR and NR patients according to their SUVmean and TV 
as measured by FLAB. 
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Table captions 
Table I: Patient demographic and clinical characteristics 
Table II: Image derived parameters definition and associated summary statistics. 
Table III: Kruskal-Wallis test results for each parameter considering the ability to 
differentiate (p<0.05) each pair of response group. 
Table IV: ROC analysis results with area under the curve (AUC) and associated 95% 
confidence intervals (CI), specificity (sp) and sensitivity (se) for each parameter 
regarding the two classification tasks. 
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